Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 4/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30106564 | 1.00 | PDGFRA (0.60) | PDGFRAKDRPDGFRBHSPB1MAPT | |
| SCHEMBL3913550 | 0.91 | PDGFRA (0.53) | PDGFRAKDRHSPB1MAPTBLM | |
| SCHEMBL3914239 | 0.89 | MET (0.52) | PDGFRAKDRMAPTSMN1; SMN2LMNA | |
| SCHEMBL15338440 | 0.87 | PDGFRA (0.48) | PDGFRAKDRHSPB1MAPTBLM | |
| SCHEMBL21198888 | 0.87 | PDGFRA (0.55) | PDGFRAKDRMAPTSMN1; SMN2KDM4E | |
| SCHEMBL1893278 | 0.87 | AXL (0.58) | PDGFRAKDRPDGFRBHSPB1MAPT | |
| SCHEMBL21753535 | 0.85 | PDGFRA (0.59) | PDGFRAKDRPDGFRB | |
| SCHEMBL30106528 | 0.85 | PDGFRA (0.59) | PDGFRAKDRPDGFRB | |
| SCHEMBL558651 | 0.84 | PDGFRA (0.80) | PDGFRAKDRPDGFRBMET | |
| SCHEMBL3911297 | 0.84 | AXL (0.60) | PDGFRAKDRPDGFRBMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-12-16 | — | — | US | disclosed |
| CN-116763787-A | New application of quinoline compound | 安徽中科拓苒药物科学研究有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023168740-A1 | NOVEL USE OF QUINOLINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-111303024-B | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-112236430-B | Cyclopyrazolone formamide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| CN-110857293-B | Novel quinoline derivative inhibitor | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-3906234-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | Array BioPharma Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885PDGFRB 30/4885 |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | CSF1R, CSF3R, FLT3 | PDGFRA 161/4885KDR 135/4885PDGFRB 136/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | PDGFRA 1572/4885KDR 22/4885PDGFRB 2152/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | PDGFRA 1743/4885KDR 60/4885PDGFRB 2655/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | PDGFRA 63/4885KDR 4/4885PDGFRB 30/4885 |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | AXL, WEE1, FLT3 | PDGFRA 236/4885KDR 73/4885PDGFRB 193/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | PDGFRA 1743/4885KDR 60/4885PDGFRB 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.